BIBO 3304

Drug Profile

BIBO 3304

Latest Information Update: 03 Apr 2007

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Basic amino acids; Peptides
  • Mechanism of Action Neuropeptide Y receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 13 Oct 2003 No development reported - Preclinical for Obesity in Italy (unspecified route)
  • 14 Jun 2001 No-Development-Reported for Obesity in Germany (Unknown route)
  • 14 Jun 2001 Preclinical development for Obesity in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top